



BostonBioForum 2015


2015 CABA Annual Conference

二〇一五美中生物医药协会年会

SHAPING THE BIOMEDICAL INDUSTRY THROUGH COLLABORATIVE INNOVATION

Topics:

- 1) Emerging Technologies for Future Therapeutics
- 2) R&D Pipeline for Rare Inherited Diseases
- 3) Accessing Innovation from Academia
- 4) Perspectives on the CRO Market and Innovation in China
- 5) Innovative Business Models in the Pharmaceutical Industry





BostonBioForum 2015

2015 CABA ANNUAL CONFERENCE 二〇一五美中生物医药协会年会

Time: 9:00AM to 9:00 PM (Saturday, May 9, 2015)

Venue: The Doubletree Suites by Hilton Hotel Boston

Address: 400 Soldiers Field Road, Boston, MA 02134

Parking: Complimentary garage parking (receive your voucher at registration desk)

Topics:

- 1) Emerging Technologies for Future Therapeutics
- 2) R&D Pipeline for Rare Inherited Diseases
- 3) Accessing Innovation from Academia
- 4) Perspectives on the CRO Market and Innovation in China
- 5) Innovative Business Models in the Pharmaceutical Industry

Admission

CABA members: FREE; Non-members: \$30. On-site enrollment to be CABA member is available (annual membership fee: \$30; lifetime membership fee: \$200)

Dinner reception: \$55. Dinner pre-registration required. Limited tickets available.

Conference Organizing Committee

Chair

ERIC X. SHI

Co-Chairs

YIN CHEN SUSAN QU BO YING

Committee Memebers

QINGQING CAO
SHUJIA DAI
HAO LI
JIAN SHAO
ZHIYONG YANG
LIPING ZHOU

QINGLIN CHE
ELLEN FAN
JEANNIE LI
ZHAOKUI WAN
YOUXIN ZHANG

ZHIHONG CHEN
JEFF HANG
CARRIE LIU
YIHAN WANG
PHILLIP ZHANG

CHAOYANG DAI
JO LEE
SHIWEN LIN
WENDY YANG
XIAOYONG ZHAO



AGENDA

- 09:00 -10:00 am Registration / Vendor Show
10:00 -10:05 am Opening Remarks, *Eric X. Shi, Ph.D.*, Conference Chair
10:05 -10:15 am Introduction of CABA, *Zhiyong Yang, Ph.D.*, CABA President

SESSION I – Perspectives from Industrial and Academic Research on Innovation

SESSION CHAIR: *Wendy Yang, MBA*

- 10:15 -10:50 am **Considerations for Developing a R & D Pipeline for Rare Inherited Diseases**
Seng H. Cheng, Ph.D., Head of Research and Early Development, Rare Diseases Science, Genzyme, a Sanofi Company
- 10:50 -11:25 am **Accessing Innovation from Academia: New Types of Industry / Academic Institutes**
Peter H. Reinhart, Ph.D., Director, Institute of Applied Life Sciences, University of Massachusetts
- 11:25 -12:00 pm **Advancing Medical Science and Enhancing Portfolio Opportunities Through More Open Collaboration**
Craig Wegner, Ph.D., Exec. Dir. & Head, Boston Emerging Innovations Unit, AstraZeneca
-  12:00 - 01:30 pm Luncheon Seminar and Vendor Show
Moderator: *Daniel Dai, Ph.D.*
Speakers from Viva Biotech, Boston-PBSS, and AccelaChem



SESSION II – Pharmaceutical & Biotech Industry in China: Today and Tomorrow

SESSION CHAIR: *Yihan Wang, Ph.D.*

- 01:30 - 02:05 pm **Collaboration. Convergence. Innovation Redefined**
Hui Cai, Ph.D., VP, Corporate Alliance, WuXi AppTec
- 02:05 - 02:40 pm **Perspectives on the China CRO Market**
Jim Li, Ph.D., CEO, Sundia MediTech Group
-  02:40 - 03:00 pm **Break**

SESSION III – Innovation: Different Approaches, Same Driving Forces

SESSION CHAIR: *Zhihong Chen, Ph.D.*



- 03:00 - 03:35 pm **From Academia to Start-up: Targeting Growth Factors in the Extracellular Microenvironment**
Katherine J. Turner, Ph.D., SVP & CSO, Scholar Rock
- 03:35 - 04:10 pm **A Tale of Two Cities: Drug Discovery Innovation in Boston and Shanghai**
Zhong Zhong, Ph.D., VP of External Research and Innovation, Vertex
- 04:10 - 05:00 pm Career Development Panel Discussions
Moderator: *Bo Ying, Ph.D.*
Panelists:
Lauren Celano, MBA, CEO, Propel Careers
Shanthi Ganesh, Ph.D., Associate Director, Dicerna Pharmaceuticals, Inc.
Yihan Wang, Ph.D., President and CEO, Shenzhen TargetRx, Inc.
Yueming Wang, MBA, a Board Member and the CEO of Zhongyuan Pharmaceutical Co., Ltd
-  5:00-6:00 Networking / Vendor Show

Session IV - Biomedical Innovation Breakthroughs

- 6:00-6:15 CABA 2014-2015 Summary and New Leadership Team 2015-2016 Announcement
Shiwen Lin, Ph.D. and *Zhiyong Yang, Ph.D.*, CABA Board Chairman and President
- 6:15-7:00 **Keynote speech:** Molecular Technology for Interrogating Biological Systems
Feng Zhang, Ph.D., Professor, Department of Brain and Cognitive Sciences, MIT
-  7:00-9:00 Dinner and Networking



Excellence in Innovation Award

to

Feng Zhang, PhD

Broad Institute of MIT and Harvard

for

the innovative optogenetics and genome engineering approaches
(TALENs and CRISPR) to understand nervous system function and disease

Boston BioForum 2015
Chinese American BioMedical Association





*Leadership in Community
Service Award*

to

Zhiyong Yang, PhD

Boston BioForum 2015
Chinese American BioMedical Association



*Leadership in Community
Service Award*

to

Susan Qu, PhD

Boston BioForum 2015
Chinese American BioMedical Association



*Leadership in Community
Service Award*

to

Shiwen Lin, PhD

Boston BioForum 2015
Chinese American BioMedical Association





*Dedicated Community
Service Award*

to

Qingqing Cao, PhD

Boston BioForum 2015
Chinese American BioMedical Association

CABA

*Dedicated Community
Service Award*

to

Yin Chen, PhD

Boston BioForum 2015
Chinese American BioMedical Association

CABA

*Dedicated Community
Service Award*

to

Zhendong Zhu, PhD

Boston BioForum 2015
Chinese American BioMedical Association

CABA

*Dedicated Community
Service Award*

to

Liping Zhou, PhD

Boston BioForum 2015
Chinese American BioMedical Association

CABA

*Dedicated Community
Service Award*

to

Jeff Hang, PhD

Boston BioForum 2015
Chinese American BioMedical Association

CABA

*Dedicated Community
Service Award*

to

Ellen Fan

Boston BioForum 2015
Chinese American BioMedical Association

CABA



SPEAKERS

**Considerations for Developing a R&D Pipeline for Rare Inherited Diseases**

Seng H. Cheng, Ph.D. Head of Research and Early Development, Rare Diseases Science, Genzyme, a Sanofi Company

Dr. Seng Cheng is Head of Research and Early Development of the Rare Diseases Division at Genzyme, a Sanofi Company. He received his B.Sc. and Ph.D. degrees in Biochemistry from the University of London, UK and trained as a postdoctoral fellow at the National Institute for Medical Research in London in the field of tumour biology. He worked as a Staff Scientist at Integrated Genetics Inc., and later joined Genzyme Corporation to work on several discovery projects including the structure and function of the cystic fibrosis transmembrane conductance regulator. As Group Vice President of Genetic Diseases Science at Genzyme, he also managed the development of novel gene delivery systems as well as translational research in genetic diseases, a number of which transitioned to clinical testing. Dr Cheng's current areas of focus include inherited metabolic, muscle, lung and neurodegenerative diseases. He has co-authored 249 research articles and reviews, and is a named co-inventor on 57 issued patents in the area of biotechnology. In his current position, he is responsible for directing the translational research and early clinical development activities in rare genetic diseases.

**Accessing Innovation from Academia: New Types of Industry/Academic Institutes**

Peter H. Reinhart, Ph.D. Director, Institute for Applied Life Sciences (IALS)

*Clinical Professor Biochemistry & Molecular Biology
University of Massachusetts, Amherst*

Dr. Reinhart is a results-focused biopharmaceutical executive with over 20 years of R&D management experience in academia (Duke Medical Center), biotechnology companies (Cogent Neuroscience, Proteostasis Therapeutics, and Alzheon), and large pharmaceutical companies (Wyeth, Pfizer), in the field of orphan diseases, neurodegenerative and respiratory diseases, diseases of ion channels, and novel technology platforms. Dr. Reinhart Initiated and led project teams that have delivered more than a dozen clinical candidates for indications ranging from Alzheimer's disease, Parkinson's disease, Huntington's disease, to ALS, CF, and stroke. He has consistent track record of building strategic leadership teams, creating innovative drug discovery and technology programs, in licensing enabling assets, establishing effective alliances and collaborations, and delivering

first-in-class clinical candidates and technologies.

Dr. Reinhart is dedicated to translating innovative ideas into novel therapeutics and medical devices.

As Director of the Institute for Applied Life Sciences (IALS), Dr. Reinhart is accelerating translational life sciences research at UMass, to facilitate industry partnerships and collaborations leading to the co-development of novel wearable devices, therapeutic candidates, and new drug and nutraceutical delivery technologies to benefit human health and well-being.

Dr. Reinhart was awarded his Ph.D. degree from the Australian National University, in Canberra, Australia, followed by postdoctoral studies as a von Humboldt Fellow with Prof. Berndt Hamprecht, at the University of Tuebingen, Germany. In 1989 he joined the laboratories of Drs. Irwin Levitan and Chris Miller at Brandeis University to study the second-messenger mediated regulation of ion channels. In 1991 he joined the faculty at Duke University Medical Center, became a tenured Associate Professor of Neuroscience 1998, and an adjunct Associate Professor in 2004. The focus of his studies was the modulation of K⁺ channels and the role of channelopathies in neurodegenerative diseases.

Dr. Reinhart has published over 100 peer-reviewed manuscripts, reviews, and book chapters, is a regular reviewer for numerous journals as well as grant review bodies, and serves on the board of several biotechnology companies.

Advancing Medical Science and Enhancing Portfolio Opportunities Through More Open Collaboration

Craig Wegner, Ph.D. Exec. Dir. & Head, Boston Emerging Innovations Unit, Scientific Partnering & Alliances, AstraZeneca IMED R&D



Dr. Wegner is a passionate translational scientist and strategic leader with over 25 years of academic and biopharmaceutical research experience. He has published peer-review manuscripts, review articles and led small initiative through to large department teams across a number of disease areas and disciplines. Presently, Craig champions an internal Ideation Team, manages AZ's partnership with the NIH/N-CATS and Taiwan NRPB, and leads AstraZeneca's expanding Open Innovation efforts of partnering internal assets (e.g., compounds) and knowhow with the disease insight and expertise of academic physician- and basic-scientists to collaboratively advance pioneering research and therapies for the benefit of patients.

**Collaboration. Convergence.
Innovation Redefined**

*Hui Cai, Ph.D. VP, Corporate
Alliance, WuXi AppTec*

Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances and Head of PR and Corporate Communications.

Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS) and a member of ACS national committee on Chemistry and Public Affairs. She is also a member of the Advisory Council of UCSD IRPS 21st Century China Program, and a member of BayHelix. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her B.S. and M.S. in Chemistry from Peking University, Ph.D. from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.

**Perspectives on the China CRO Market**

*Jim Li, Ph.D. CEO, Sundia MediTech
Co., Ltd.*

Dr. Jim Li is Chief Executive Officer of Sundia MediTech Co., Ltd. Prior to his current role, Dr. Li was Chief Technology Officer and led the Company's Process & Development and Analytical Research & Development departments, overseeing business development and daily operations including API manufacturing and CMC coordination. Before joining Sundia, Dr. Li spent 18 years working in a variety of positions at a global CRO as well as leading pharmaceutical companies and research institutions, including Wuxi, Wyeth and Cognis. During Dr. Li's 10-year tenure with Wyeth, he participated in and led numerous drug discovery research programs, including successfully delivering development track compounds for treatment of various diseases such as COPD and Asthma.

Dr. Li received a B.S. in Chemistry from Wuhan University, a M.S. in Polymer Science from the Institute of Chemistry, Chinese Academy of Science and a Ph.D. in Organic Chemistry from the University of Central Lancashire, and completed his postdoctoral fellowship at the University of Chicago. To date, Dr. Li has 57 publications and patents.

**From Academia to Start-up: Targeting
Growth Factors in the Extracellular
Microenvironment**

*Katherine J. Turner, Ph.D. Senior Vice
President, Research, Scholar Rock, Inc.*



Dr. Turner is an accomplished biotechnology executive and entrepreneur. She is currently Senior Vice President, Research at Scholar Rock, Inc., which is focused on discovering and developing a new class of biologic therapies, "niche modulators," that selectively target dysregulated growth factors in the disease microenvironment. Prior to Scholar Rock, she has served as Vice President at such pioneering companies as Genetics Institute (Protein Discovery), Wyeth (Immunology), and Biogen Idec (Validation Biology). In addition, Dr. Turner has played key scientific leadership roles in start-up companies including Attogen, Inc. Her extensive research and managerial experience encompasses more than 30 years of involvement with all aspects of therapeutic biologics discovery through early clinical development. Her areas of therapeutic expertise include immunology, oncology, hematopoiesis, neurobiology and tissue repair and fibrosis. Dr. Turner has been responsible for the advancement of several therapeutic monoclonal antibodies and played important roles in the development of Neumega®, GM-CSF, PSGL-Ig and IL-13 antagonist.

Dr. Turner received her Ph.D. in Biochemistry from Virginia Tech, and pursued post-doctoral training at the Courtauld Institute for Biochemistry (London University) and Brandeis University.

**A Tale of Two Cities: Drug Discovery
Innovation in Boston and Shanghai**

*Zhong Zhong, Ph.D. VP, External
Research and Innovation, Vertex*



Dr. Zhong is VP of External Research and Innovation at Vertex Pharmaceuticals Inc. He worked as the General Manager for Vertex Pharmaceuticals China R&D site and prior to that Head of Neuroinflammation DPU at



GlaxoSmithKline in Shanghai. He has held senior positions at the same R&D center since 2008, leading the Discovery Technology department and Regenerative Medicine Discovery.

Dr. Zhong did his undergraduate studies at Fudan University and earned his Ph.D. at the Rockefeller University. He was a Howard Hughes Postdoc Fellow of the Life Sciences Research Foundation trained by Dr. Richard Axel at the Columbia University. He worked in US at Johnson & Johnson Pharma R&D, Cell & Molecular Technologies Inc., and Invitrogen (now Life Technologies) prior to his GSK position.

PANELISTS



Lauren Celano, MBA
CEO
Propel Careers

Lauren Celano is the Co-founder and CEO of Propel Careers, a life science search and career development firm focused on connecting talented individuals with entrepreneurial innovative life sciences companies. Lauren is very passionate about working with individuals with strong scientific backgrounds to find exciting growth opportunities in the life sciences industry. Before Propel, she spent about 10 years in the life sciences industry working with companies to advance drug molecules through SNBL USA, Aptuit, Quintiles, and Absorption Systems. She has a B.S. in Biochemistry and Molecular Biology from Gettysburg College and an MBA with a focus in the health sector and entrepreneurship from Boston University. Lauren is on the Board of MassBioEd, the Advisory Board of the Boston University School of Public Health Pharmaceuticals Program, and the Advisory board for Endicott College Boston. She also serves on the programming committee of the Capital Network.



Shanthi Ganesh, Ph.D.
Associate Director
Dicerna Pharmaceuticals, Inc.

Shanthi Ganesh has broad background in Oncology, with specific training in key research areas. As a Research Investigator at Novartis Institutes for BioMedical Research, she mainly focused on utilizing RNAi therapeutics for oncology applications. She led a group of 15 people with variety of different skill sets (chemistry, formulation, biology and pharmacology) to come with innovative targeted strategies to enhance the tumor delivery. While working at Novartis, she also went to Northeastern University to get her Ph.D. in the

same field. Since graduation, she has been invited several times to give guest lectures on drug delivery, nucleic acid therapeutics and gene therapy at Northeastern University.

Prior to joining Novartis, she worked at 2 major Gene therapy companies where she designed, developed and evaluated oncolytic viruses for treatment of cancer. Two of the oncolytic viruses she worked on reached clinic to treat patients with neuroendocrine tumors and urinary bladder cancer. Currently she is working at Dicerna Pharmaceuticals as an Associate Director evaluating the company's novel RNAi delivery systems in disseminated leukemia models and several solid tumors for multiple cancer indications. During her career, she published extensively in siRNA and cancer therapeutics area. She also holds several patents and awards for her work in siRNA and oncology area. She has also been a member of ASGT and AACR for the last several years and attended and presented her work at these international conferences.

Yihan Wang, Ph.D.
President and CEO
Shenzhen TargetRx, Inc.



Dr. Wang founded Shenzhen TargetRx, Inc., in Aug 2014 and is now the President/CEO. He was the Associate Director of Chemistry at ARIAD Pharmaceuticals, Inc., until April 2013. Yihan Wang received his B.Sc. in chemistry from University of Science and Technology of China, and Ph.D. in chemistry from New York University. Yihan's research has focused primarily on medicinal chemistry in the area of signal transduction drug discovery, integrating structure-based drug design, combinatorial chemistry, and both biological and pharmacological assays to identify small-molecule clinical candidates. His career at ARIAD includes innovative research in therapeutic areas involving bone diseases and cancer, and has been a key contributor to the discovery of several clinical drugs, including Ponatinib (iClusig™) (approved by the FDA for resistant CML in



Dec 2012), Brigatinib (AP26113, Phase II for NSCLC), Ridoforolimus (Phase III for Sarcoma and multiple Phase II), and several pre-clinical compounds. Yihan is the primary author of approximately 90 peer-reviewed publications, patents, and invited meeting talks. Yihan is the editor of "Chemical Biology and Drug Design" and a reviewer for many professional journals. Yihan is one of the co-founders of Chinese-American BioMedical Association (CABA) and currently on the Board of Directors.



Yueming Wang, MBA
Board Member and CEO
Zhongyuan Pharmaceutical Co., Ltd

Yueming Wang, MBA, IPEM, is a Board Member and the CEO of Zhongyuan Pharmaceutical Co., Ltd, in Beijing, a new affiliation of Zhongyuan Union Stem & Cell Engineering Corporate Co., Ltd, in Tianjin, a listed company in China. Yueming joined the Zhongyuan Union in early 2014 and has been serving as the Director of Human Resources and Chairman of Alliances Biosciences., Ltd, another affiliate of the Zhongyuan Union.

In January 2015, Yueming completed his master program courses in International Pharmaceutical Engineering Management (IPEM) at Peking University. He obtained his MBA from Maryville University St. Louis, U.S., and returned home in May 1998. He worked for Beijing Tide Pharmaceutical Co., Ltd, as Deputy General Manager in charge of human resources and pharmaceutical/R&D facility construction projects between October 1999 and January 2014.

DINNER RECEPTION KEYNOTE



Molecular Technology for Interrogating Biological Systems

Feng Zhang, Ph.D. Professor, Department of Brain and Cognitive Sciences, MIT

Dr. Feng Zhang is the Keck Career Development Assistant Professor of Neuroscience and Biological Engineering at MIT, a New York Stem Cell Foundation-Robertson Investigator and a Core Member of the Broad Institute of MIT and Harvard. As a graduate student at Stanford University, Zhang worked with advisor Karl Deisseroth to invent a set of technologies for dissecting the functional organization of brain circuits. His lab works on developing and applying disruptive technologies including optogenetics and genome engineering (TALENs and CRISPR) to understand nervous system function and disease. Zhang's long-term goal is to develop novel therapeutic strategies for disease treatment. He obtained a bachelor's degree from Harvard University and a Ph.D. in chemistry and bioengineering from Stanford University. Before joining the MIT faculty he was a junior fellow of the Harvard University Society of Fellows. He is a recipient of the Waterman Award from the National Science Foundation, the Perl/UNC Prize in Neuroscience, the NIH Director's Pioneer award, and awards from the Searle Scholars Program, McKnight, Keck, Vallee, and Damon Runyon foundations.

Thank you for coming and have a great evening!



PLATINUM SPONSOR



GOLD SPONSORS



SILVER SPONSORS



CONFERENCE SPONSORS



MEDIA PARTNERS



Scan each QR code to explore more!



2015-2016 CABA LEADERSHIP TEAM

President (2014-2015)

Zhiyong Yang, Ph.D.
Senior Principal Scientist, Pfizer
BioTherapeutics Research

President (2015-2016)

Susan Qu, Ph.D. MBA
External Manufacturing Integrated Risk
Manager, Genzyme, a Sanofi Company

President Elect (2016-2017)

Eric Shi, Ph.D.
Investigator, GSK

VP of Communications

Qinglin Che, Ph.D.
Senior Scientist, Synta Pharmaceuticals

VP of Finance

Zhendong Zhu Ph.D.
Principal Investigator, Celgene Avilomics
Research

General Manager of Business Relations

Qingqing Cao, Ph.D.
Senior Engineer, Becton Dickinson
(BD)-Bioscience

General Manager of Operations

Ellen Fan
Senior Scientist, Arsenal Medical

Treasurer

Liping Zhou Ph.D.
Senior Scientist, Ipsen

CABA Legal Counsel

Fred Gilman, J.D.
Attorney, Lynch, DeSimone & Nylen, LLP

Board of Directors

Shiwen Lin, Ph.D.
Chairman of the Board
Director, Process & Analytical Technologies,
Agenus, Inc.

Zhihong Chen, Ph.D.
CABA President (2011-2012)
CSO, Found Medicine LLC

Chaoyang Dai, Ph.D.
CABA President (2010-2011)
President, Boston BioSolutions

Jun Han, Ph.D.
CABA Founding President
CEO, SOTA International LLC

Lixin Shen, Ph.D.
President and CEO, Wuxi Howfond Biopharma
Co., Ltd.(China)

Zhao-Kui Wan, Ph.D.
CABA President (2009-2010)
Head of Medicinal Chemistry, Janssen
Pharmaceutical Companies of Johnson &
Johnson(China)

Yihan Wang, Ph.D.
Past Board Chair
President, Shenzhen TargetRx, Inc.

Erxi Wu, Ph.D.
Assistant Prof., North Dakota State University

Junjun Wu, Ph.D.
CABA President (2007-2009)
CEO, WuXi AllNature Biotech LLC(China)

Zhiyong Yang, Ph.D.
CABA President (2014-2015)
Senior Principal Scientist, Pfizer, BioTherapeutics
Research

Xiang Yang Yu, Ph.D.
CABA President (2013-2014)
Program Manager at Accellient Partners, LLC

Philip Zhang, Ph.D., J.D.
CABA President (2012-2013)
Co-Managing Principal, Milstein Zhang & Wu LLC

CABA Advisors

Youssef Bennani, Ph.D.
Site Head,
Vertex Pharmaceuticals Inc.-Canada

Tim Clackson, Ph.D.
President of Research and Development
and Chief Scientific Officer, Ariad
Pharmaceuticals Inc.

Yuan-Hua Ding, Ph.D.
Senior Director & Head of External R&D
Innovation - Asia, Pfizer

Pierre Dodion, M.D., MBA
Senior VP, Corporate Development, Ariad
Pharmaceuticals Inc.

Chen Li, Ph.D.
CEO, Hua Medicine (China)

Luke Li, Ph.D.
Exec Director, Head of Global Biothera-
peutic Technologies, Bio-Innovation,
Pfizer

Yuanli Liu, Ph.D.
Director of China Initiative, Harvard
School of Public Health

Dawei Ma, Ph.D.
Professor, Shanghai Institute of Organic
Chemistry (China)

Tarek Mansour, Ph.D.
EVP of Research & Development, Xenon
Pharmaceuticals (Canada)

Shi Li, Ph.D.
CEO, Zerun Biotechnology (China)

Tse Ping
Chairman, Sino Biopharmaceutical
Ltd.(China)

John Pivinski, Ph.D.
Principal, JJPivinski Pharma Consulting
LLC

Steve Projan, Ph.D.
Senior VP, R&D, Innovative Medicines Head
of Infectious Diseases & Vaccines,
MedImmune

Tomi Sawyer, Ph.D.
Distinguished Scientist & Head, Peptide
Drug Discovery and Innovative Technol-
ogies at Merck Research Laboratories

Liming Shao, Ph.D.
Professor, Fudan University (China)

Suvit Thaisrivongs, Ph.D.
Vice President, Pfizer

Roger Tung, Ph.D.
CEO, Concert Pharmaceuticals

Yibin Xiang, Ph.D.
CSO, Sanhome Pharma

Gangfeng Xu, Ph.D.
Divisional Vice President, Corporate
Licensing & Acquisitions at Abbott
Laboratories

Steve Yang, Ph. D.
Executive VP & COO, Wuxi Aptec

Howard Yuwen, Ph. D.
Co-founder & VP Corporate Development &
Regulatory Affairs, Genesun Pharmaceuti-
cals

Executive Committee Members

Yin Chen, Ph.D., MBA
Director of Business Development (Consultant), Acclagen

Shujia (Daniel) Dai, Ph.D.
Principle Research Investigator, Sanofi-Aventis

Kevin Fang, Ph.D.
Senior Director of Medicinal Chemistry, Sunovion
Pharmaceuticals

Henry Gu, J.D.
Director, IP Counsel, Cubist Pharmaceuticals

Jeff Hang, Ph.D.
Regulatory & Quality System Consultant, Makromed Inc

Jinbo Lee, Ph.D.
Cofounder & CSO, Scilligence Corp.

Jo Lee, M.Ec.
Founder, Somebusiness, Inc.

Hao (Howard) Li, Ph.D., MBA
Cambridge Site Head, Novartis Knowledge Center, Novartis

Jing (Jeannie) Li, Ph.D.
Post-doctoral Fellow, Pfizer

Carrie Liu, Ph.D.,
Associate Director of Analytical Chemistry, Concert
Pharmaceuticals

Sue Ma, M.D.
Scientist II, Novartis Institute of Biomedical Research

Jian Shao, MBA (expected in May 2015)
Yale School of Management

Ze Tian, Ph.D.
Staff Scientist, Curis

Yueming Wang, MBA
Board Member and the CEO
Pharmaceutical Co., Ltd., Beijing

Zhigang Wang, Ph.D.
Principal Scientist, Celgene Avilomics Research

Li Xing, Ph.D.
Senior Principal Scientist, Pfizer

Wendy Yang, MBA
Senior Project Manager, Genzyme
Corporation, a division of Sanofi

Bo Ying, Ph.D.
Senior Scientist, Onkaido Therapeutics, a Moderna Venture

Jingzhong (Jeff) Zhang, Ph.D.
Senior Scientist, Medica Corp

Wei Zhang, Ph.D.
Staff Scientist, Siemens Healthcare Diagnostics

Youxin Zhang, Ph.D.
Senior Consultant, Navigant Consulting

Xiaoyong Zhao, Ph.D.
Senior Scientist, Momenta

CABA thank the dedicated service from the 8 retired EC this year:

Shallwei Sun, Wendy Zhang, Shengfang Jin, Fred Hu, Yikai Wang, Lan Cao, Ji Shi, and Yongzhong Wang.

Chinese-American BioMedical Association

美中生物医药协会



CABA Mission Statement

- To promote science, technology, and business collaboration in biotech/pharmaceutical industry ;
- To build and maintain a platform through cohesive scientific, professional, and cultural connection that provides high quality services;
- To facilitate networking among scientists, professionals, and entrepreneurs in academia, biotech/pharmaceutical industry and regulatory agencies;
- To embrace advancement of science and commercialization of innovation that will benefit human health;
- To foster collaborations between the United States and China for the development of better biotech/pharmaceutical therapeutics.

About CABA

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potential.

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves its members.

Contact Us

If you have any comments, suggestions or feedback to our organization and our events, please feel free to contact us at cabaconnect@gmail.com. Your comments are important for us to improve in the future. Thank you very much!

Website: www.cabaweb.org
Email: cabaconnect@gmail.com
P. O. Box 426157
Cambridge, MA 02142

